CVS Caremark Reaches New 52-Week High (CVS)

NEW YORK ( TheStreet) -- CVS Caremark (NYSE: CVS) hit a new 52-week high Thursday as it is currently trading at $60.71, above its previous 52-week high of $60.70 with 2.2 million shares traded as of 12:55 p.m. ET. Average volume has been 5.1 million shares over the past 30 days.

CVS Caremark has a market cap of $73.65 billion and is part of the services sector and retail industry. Shares are up 23.8% year to date as of the close of trading on Wednesday.

CVS Caremark Corporation, together with its subsidiaries, provides integrated pharmacy health care services in the United States.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates CVS Caremark as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full CVS Caremark Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Goldman Bankers (Mostly) Upbeat on Tech M&A and IPO Trends

Goldman Bankers (Mostly) Upbeat on Tech M&A and IPO Trends

Why a Walgreens Purchase of Humana or WellCare Now Appears Less Likely

Why a Walgreens Purchase of Humana or WellCare Now Appears Less Likely

5 Awesome Stock Picks That Will Survive a Choppy Market

5 Awesome Stock Picks That Will Survive a Choppy Market

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget